Veracyte Announces Third Quarter 2019 Financial Results and Business Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Veracyte (VCYT) Tops Q3 EPS by 5c, Slight Beat on Revenue; Reaffirms FY19 Revenue Outlook
October 22, 2019 4:17 PM EDTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.02), $0.05 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $31 million versus the consensus estimate of $30.1 million.
Third Quarter 2019 Financial Results
For the third quarter of 2019 as compared with the third quarter of 2018:
Revenue was $31.0 million, an increase of 32%; excluding $4.3 million of biopharmaceutical services revenue, revenue was $26.7 million, an increase of 15%.Gross... More